MabThera International Trial - Homepage
MInT-Study
Randomised Intergroup Trial of First Line Treatment for Patients with Diffuse Large B-Cell Lymphoma with a CHOP-Like Chemotherapy Regimen with or without the CD20 antibody Rituximab (MabThera, IDEC-C2B8).
MInT-Follow-Up-Study
Follow-Up Observational Study of the Randomised Intergroup (MinT) Trial.